Is Vancomycin/Piperacillin-tazobactam combination associated with higher rates of AKI?
Adeyemo Abiodun explains it beautifully with his visual abstract
And luckily this chat has another wonderful visual abstract by PS Vali.
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
Is Vancomycin/Piperacillin-tazobactam combination associated with higher rates of AKI?
Adeyemo Abiodun explains it beautifully with his visual abstract
And luckily this chat has another wonderful visual abstract by PS Vali.